XML 52 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LICENSE, COLLABORATION AND OTHER REVENUE (Tables)
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenues Recognized from License, Collaboration and Other Significant Agreements
The Company recognized the following revenue from its license, collaboration and other revenue agreements (in thousands):
 Three Months Ended June 30,Six Months Ended June 30,
EntityDescription2024202320242023
Medice License and Product Supply of Vafseo in EU$— $10,000 $— $10,000 
MTPCLicense and Product Supply of Vafseo in Japan1,169 516 1,581 4,678 
JT and Torii License and royalties related to the sale of Riona in Japan1,270 1,391 2,456 2,528 
Otsuka Terminated U.S. and International Agreements— 2,225 — 2,225 
Total license and other revenue $2,439 $14,132 $4,037 $19,431 
Changes in Contract Assets and Liabilities
The Company had the following deferred revenue balances as of June 30, 2024 (in thousands):
 June 30, 2024
Deferred Revenue:Short-TermLong-TermTotal
CSL Vifor License Agreement$43,296 — $43,296 
Total$43,296 $— $43,296 
The following tables present changes in the Company’s contract assets and liabilities related to license and other revenue (in thousands):
Six Months Ended June 30, 2024
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract asset:    
Accounts receivable(1)
$3,333 $4,037 $(5,542)$1,828 
Contract liability:
Deferred revenue$43,296 $695 $(695)$43,296 
Six Months Ended June 30, 2023
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable(1)
$1,901 $943 $(2,319)$525 
Prepaid expenses and other current assets$781 $— $(781)$— 
Contract liabilities:
Deferred revenue$47,034 $— $(3,738)$43,296 
 (1) Excludes accounts receivable related to amounts due to the Company from product sales of Auryxia which are included in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and 2023.
Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities
The Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands): 
Three Months Ended June 30,Six Months Ended June 30,
Revenue Recognized in the Period:2024202320242023
Deferred revenue — beginning of the period$— $— $— $3,738